US healthcare stocks took a hit on Tuesday, even as two of the sector's biggest names reported better-than-expected quarterly earnings. The culprit: Johnson & Johnson's updated profit forecast for 2026 didn't go far enough to satisfy Wall Street, and investors punished the stock accordingly.
The NYSE Healthcare Index fell 1.1%, while the Health Care Select Sector SPDR Fund (XLV) dropped 1.2% and the iShares Biotechnology ETF (IBB) slid 1.6%. The moves show how a single heavyweight's guidance can ripple through the entire sector.
J&J's beat wasn't enough
Johnson & Johnson, the pharmaceutical and medical-devices giant, reported adjusted earnings per share (EPS) of $2.59 for the third quarter, topping the $2.52 analysts had expected. The company also raised its 2026 adjusted EPS guidance to a range of $11.05 to $11.15.
But that range still fell short of the $11.19 consensus estimate tracked by FactSet. Investors reacted sharply, sending J&J shares down more than 6% on the day.
This is a classic case of "good news, bad reaction." In the investing world, beating the current quarter's numbers often matters less than what a company signals about the future. When a company raises its outlook but still lands below what analysts had penciled in, it can trigger a wave of downward revisions to profit forecasts and a reassessment of the stock's valuation.
UnitedHealth and Lilly: different stories, same outcome
UnitedHealth, the largest US health insurer, had the opposite setup. It beat estimates with adjusted EPS of $4.69 versus $4.14 expected, and it raised its 2026 outlook to at least $20.50. Yet its stock only managed a modest 0.2% gain.
Even Eli Lilly, a drugmaker that received UK regulatory clearance for its Onswik insulin for adults with type 2 diabetes from the Medicines and Healthcare products Regulatory Agency, saw its shares fall 1.1%. The regulatory win was positive news, but it wasn't enough to offset the broader sector's downbeat mood.
The takeaway: markets often care more about the size of future expectations than today's beat. A single quarter's outperformance can be overshadowed by a guidance that disappoints.
Why guidance matters so much
Guidance is where investors anchor their longer-term forecasts. When a company raises its outlook but still comes in below consensus, analysts often trim their forward profit models or decide the stock deserves a lower valuation multiple. That can outweigh an EPS beat in the current quarter.
This dynamic isn't unique to healthcare. Similar patterns play out across sectors, as seen in recent moves in chip stocks where guidance and competitive threats have driven sharp swings. But in healthcare, the sector's heavyweights carry outsized weight in market-cap-weighted indexes and ETFs.
When a stock like J&J moves sharply, it can drag the entire basket down, even if other components are doing well. That's why UnitedHealth's stronger 2026 outlook and Lilly's UK regulatory win didn't stop a broader de-rating once J&J reset expectations.
What it means for investors
For everyday investors holding healthcare ETFs or mutual funds, Tuesday's action is a reminder that sector funds don't move in lockstep with every piece of good news. A single company's guidance can overshadow the positive developments from others.
It's also a lesson in how to interpret earnings season. Beating the quarter is nice, but the market's real focus is often on the forward outlook. When a company raises guidance but still misses the mark, it can signal that growth may be slowing or that competition is intensifying.
That said, one day's move doesn't define a sector's long-term prospects. Healthcare remains a diverse space, with companies ranging from insurers to drugmakers to device manufacturers, each with its own drivers. Investors should look beyond the headline numbers and consider the underlying trends.
For now, the sector's slide shows that even good news can be met with skepticism when expectations are high. As earnings season continues, watch how other companies frame their outlooks—guidance will likely be the key driver of stock moves, not just the quarterly numbers.
